Agalsidase alfa is indicated for:
Population group: both men and women, only adults (18 - 65 years old)
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Agalsidase alfa is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Agalsidase alfa is contraindicated in the following cases: